SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Rhea-AI Summary

SAB BIO (Nasdaq: SABS) will present clinical data on SAB-142 at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia), December 9-11, 2025 in Singapore. Presentations on December 10, 2025 highlight Phase 1 results reporting a multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile without serum sickness or anti-drug antibodies at the target dose.

The company said it is currently in Phase 2b development for delaying progression of new-onset Stage 3 type 1 diabetes and expects to report additional Phase 1 data and dose the first Phase 2b SAFEGUARD patient later in 2025. Presentations will be posted on the company website.

Insights

Clinical Development Strategist

SAB BIO presents Phase 1 data for SAB-142 showing mechanism, immunomodulation without prolonged lymphodepletion, and a favorable safety signal; Phase 2b dosing to begin later this year.

SAB-142 advances through clinical milestones by sharing Phase 1 evidence of a multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and no observed serum sickness or anti-drug antibodies at the target dose. These statements describe the biological activity, absence of key immune safety signals, and readiness to progress clinically. Public oral presentations at the December 9-11, 2025 ATTD-Asia conference increase scientific visibility and make the Phase 1 data available to clinicians and investigators.

The main dependencies and risks are the implicit need for replicated efficacy and confirmatory safety in the ongoing Phase 2b SAFEGUARD trial and the timing of first-patient dosing, which the company says will occur later this year. The Phase 1 observations alone do not demonstrate clinical benefit in delaying progression of type 1 diabetes; they support moving into larger trials but do not guarantee positive outcomes. Watch for formal Phase 2b enrollment milestones and any published safety or efficacy endpoints from that study over the next 6–18 months.

MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2^nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore.

Data to be presented will highlight the progress of SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the progression of T1D in new-onset, Stage 3 patients, including:

• Phase 1 study data showcasing the clinically validated, multi-specific mechanism of action of SAB-142.
• Phase 1 study data demonstrating immunomodulation without sustained lymphodepletion following dosing of SAB-142.
• Phase 1 study data demonstrating a favorable safety profile for SAB-142, characterized as not causing serum sickness or anti-drug antibodies at the target dose.
  

“We are excited to share data at another major international conference to highlight the robust multi-specific mechanism of action of our lead program, SAB-142. Our presentations at ATTD-Asia continue to support the development of SAB-142 as a potential best-in-class immunotherapy, currently in Phase 2b clinical development for delaying the progression of T1D in new-onset, Stage 3 patients,” said Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO. “We look forward to sharing additional Phase 1 data and dosing the first patient in the Phase 2b SAFEGUARD clinical trial later this year.”

Oral Presentation Details:
Title: Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes
Session: 0730 – Orals 01: Pharmacotherapy and Safety, Drugs and Biologics | Presentation ID 21
Presenter: Christoph Bausch, PhD, EVP and COO, SAB BIO
Presentation Date and Time: Wednesday, December 10, 2025 | 17:00 - 17:12 SGT
Location: Room 326

Oral E-Poster Presentation Details:
Title: Immunomodulation without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
Session:  0650 – Short Oral 07: New Medications for Treating Obesity and Diabetes Part II | Presentation ID 94
Presenter: Stan Stoyanov, MD, VP, Clinical Development, SAB BIO
Presentation Date and Time: Wednesday, December 10, 2025 | 17:25 - 17:30 SGT
Location: Station 1

Title: Safety Profile of SAB-142; A Fully Human Anti-Thymocyte Globulin
Session: 0650 - Short Oral 07: New Medications for Treating Obesity and Diabetes Part II | Presentation ID 94
Presenter: Stan Stoyanov, MD, VP, Clinical Development, SAB BIO
Presentation Date and Time: Wednesday, December 10, 2025| 15:35 - 15:40 SGT
Location: Station 1

The presentations will be made available in the Presentations section of the Company’s website at the time of the presentation and will remain accessible following the conference.

About SAB-142
SAB-142 is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new- or recent-onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of “bad acting” T-lymphocytes like cytotoxic T-cells. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.

Forward-Looking Statements
Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company’s T1D program and other discovery programs.

These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

CONTACTS

Investor Relations:
Cristi Barnett
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

FAQ

What data will SAB BIO (SABS) present about SAB-142 at ATTD-Asia on December 10, 2025?

SAB BIO will present Phase 1 data on mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile for SAB-142.

When and where are SAB BIO's SAB-142 presentations at ATTD-Asia (SABS)?

Oral and short oral presentations are scheduled on Wednesday, December 10, 2025, at ATTD-Asia in Singapore (times listed in SGT).

Who will present SAB-142 data for SAB BIO (SABS) at the conference?

Presenters include Christoph Bausch, PhD (EVP & COO) and Stan Stoyanov, MD (VP, Clinical Development).

What is SAB BIO's clinical stage for SAB-142 (Nasdaq: SABS)?

SAB-142 is in Phase 2b clinical development for delaying progression of new-onset, Stage 3 type 1 diabetes.

Will SAB BIO (SABS) share presentation materials for SAB-142 from ATTD-Asia?

Yes, presentations will be posted in the Presentations section of the company website at the time of the presentation and remain accessible after the conference.

Does SAB BIO (SABS) plan near-term clinical milestones for SAB-142 after ATTD-Asia?

The company stated it expects to dose the first patient in the Phase 2b SAFEGUARD trial later in 2025.